Disclosures for "Nurse-Reported Outcomes of Cannabidiol (CBD) Treatment in the Long-Term Care (LTC) Setting: Results From the BEhavior, COgnition, and More With Epidiolex® in the Long-Term Care Setting (BECOME-LTC) Survey"
-
Ms. Wrobel has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Jazz. Ms. Wrobel has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Neurocrinr Bioscience . Ms. Wrobel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB.
-
Mr. Shafrin has received personal compensation for serving as an employee of FTI Consulting.
-
Dr. Chung has received personal compensation for serving as an employee of FTI Consulting. Dr. Chung has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for FTI Consulting.
-
Mr. Thahir has nothing to disclose.
-
Dr. Rajasekaran has received personal compensation for serving as an employee of Jazz Pharmaceuticals.
-
Dr. Fowler has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Fowler has stock in Jazz Pharmaceuticals.
-
Sheila Thomas has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Sheila Thomas has stock in Jazz Pharmaceuticals.